WuXi Vaccines and BravoBio collaborate to accelerate innovative vaccines
The CDMO will provide expertise and capacity to advance BravoBio's vaccine pipeline
The recent outbreaks and epidemics have highlighted the importance of industrial collaboration and partnership. And now, WuXi Vaccines, a joint venture between WuXi Biologics and Shanghai Hile Bio-Technology focused on vaccine CDMO services, and Shanghai BravoBio have signed a Letter of Intent for long-term collaboration on accelerating the development and commercial manufacturing of innovative vaccines.
Specifically, the collaboration will focus on using WuXi Vaccines' end-to-end vaccine development and manufacturing capabilities to advance BravoBio's vaccine pipeline, which aims to address challenges from infectious diseases.
The partnership will see BravoBio utilise WuXi Vaccines’ integrated platforms to conduct preclinical research, GMP manufacturing of clinical supply and global commercial supply for its multiple innovative vaccine candidates.
In addition, the CDMO will leverage its experience and capacity to support the Investigational New Drug (IND) application and commercialication for BravoBio’s vaccine products globally.
Back in November 2019, WuXi Vaccines announced it was investing $240 million and building a new vaccine manufacturing facility in Dundalk, Ireland. The facility got underway in February 2020 and is due to be operational by 2024.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...